Verona Pharma PLC
VRNA106.910USD
0.0000.00%
終値 02/06, 16:00（ET）15分遅れの株価
73.55B時価総額
損失額直近12ヶ月PER
詳細情報 Verona Pharma PLC 企業名
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Verona Pharma PLCの企業情報
企業コードVRNA
会社名Verona Pharma PLC
上場日Mar 30, 2005
最高経営責任者「CEO」Dr. David S. Zaccardelli, Pharm.D.
従業員数209
証券種類Depository Receipt
決算期末Mar 30
本社所在地Riverside
都市LONDON
証券取引所NASDAQ Global Market Consolidated
国United Kingdom
郵便番号SE1 2RE
電話番号442032834200
ウェブサイトhttps://www.veronapharma.com/
企業コードVRNA
上場日Mar 30, 2005
最高経営責任者「CEO」Dr. David S. Zaccardelli, Pharm.D.
Verona Pharma PLCの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Andrew Fisher
Mr. Andrew Fisher
General Counsel
General Counsel
528.82K
+3488.37%
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Dr. Anders Ullman, M.D., Ph.D.
Dr. Anders Ullman, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Benjamin Lucas
Mr. Benjamin Lucas
Principal Executive Officer, Director
Principal Executive Officer, Director
--
--
Ms. Ebru Can Temucin
Ms. Ebru Can Temucin
Principal Financial Officer, Principal Accounting Officer, Director
Principal Financial Officer, Principal Accounting Officer, Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
Pentwater Capital Management LP
6.15%
HBK Investments, L.P.
4.95%
Fidelity Investments Canada ULC
4.05%
Frazier Life Sciences Management, L.P.
3.93%
Davidson Kempner Capital Management LP
3.80%
他の
77.14%
株主統計
株主統計
比率
Pentwater Capital Management LP
6.15%
HBK Investments, L.P.
4.95%
Fidelity Investments Canada ULC
4.05%
Frazier Life Sciences Management, L.P.
3.93%
Davidson Kempner Capital Management LP
3.80%
他の
77.14%
種類
株主統計
比率
Hedge Fund
41.60%
Investment Advisor/Hedge Fund
18.51%
Investment Advisor
11.73%
Research Firm
7.21%
Individual Investor
5.62%
Venture Capital
4.92%
Private Equity
4.03%
Family Office
1.16%
Pension Fund
0.30%
他の
4.92%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
467
76.61M
88.88%
-7.12M
2025Q2
423
82.86M
96.18%
-3.71M
2025Q1
406
83.91M
98.59%
+940.31K
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Pentwater Capital Management LP
--
0%
+5.30M
-100.00%
HBK Investments, L.P.
--
0%
+4.26M
-100.00%
Fidelity Investments Canada ULC
--
0%
+3.49M
-100.00%
Frazier Life Sciences Management, L.P.
--
0%
--
--
Davidson Kempner Capital Management LP
--
0%
+3.27M
-100.00%
Glazer Capital, LLC
--
0%
+3.21M
-100.00%
Ali (Behbahani)
--
0%
+3.19M
-100.00%
BlackRock Financial Management, Inc.
--
0%
+2.83M
-100.00%
New Enterprise Associates (NEA)
--
0%
-10.14K
-100.00%
Goldman Sachs & Company, Inc.
--
0%
-685.23K
-100.00%
詳細を見る
関連ETF
更新時刻: Tue, Dec 2
更新時刻: Tue, Dec 2
銘柄名
比率
iShares Disciplined Volatility Equity Active ETF
0%
AltShares Merger Arbitrage ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
Rayliant Quantitative Developed Market Equity ETF
0%
Calvert International Responsible Index ETF
0%
iShares Biotechnology ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
JPMorgan Healthcare Leaders ETF
0%
Global X Guru Index ETF
0%
詳細を見る
iShares Disciplined Volatility Equity Active ETF
比率0%
AltShares Merger Arbitrage ETF
比率0%
SPDR Portfolio Developed World ex-US ETF
比率0%
Rayliant Quantitative Developed Market Equity ETF
比率0%
Calvert International Responsible Index ETF
比率0%
iShares Biotechnology ETF
比率0%
Fidelity Nasdaq Composite Index ETF
比率0%
First Trust IPOX Europe Equity Opportunities ETF
比率0%
JPMorgan Healthcare Leaders ETF
比率0%
Global X Guru Index ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
